Developmental Research Program

医学研究报告：摘要/摘要 发展研究计划（DRP）的目的是资助高度创新的翻译研究， 结肠直肠癌（CRC）或胰腺癌（PDAC），目前缺乏人类终点， SPORE指南，但这可能成为具有必要DRP支持的完整SPORE项目，或与 成功获得SPORE机制之外的资金。DRP提供了一个独特的场所， 现有的关键财政支助以及针对具体疾病的知识和资源专长， 一个程序是迅速响应新的想法或倡议，包括从调查人员，其目前的工作 可能不会只专注于CRC或PDAC研究。该计划植根于一种合作精神， 由GI SPORE领导，它有一个广泛的跟踪记录，使调查人员从其他学科 进入CRC和/或PDAC研究领域。DRP的优势在于它有能力提供资金， 获得整个GI SPORE内的所有关键专业知识和资源所需的支持，包括 建议核心这将使我们能够开发创新的、由制造商发起的项目，这些项目有可能 发展成可靠和富有成效的转化研究项目，沿着一条从基础和/或人口 将研究项目转化为以人类临床标本/患者人群为重点的研究。DRP将与- 由SPORE的主要研究人员领导，包括谢赫科学主任Anirban Maitra博士 艾哈迈德胰腺癌研究中心，病理学系教授， UT MD安德森癌症中心（UTMDACC）的转化分子病理学和Scott Kopetz博士， 副教授兼胃肠医学系转化研究副主任 肿瘤科DRP将不仅包括UTMDACC，还包括我们的合作伙伴机构Johns 霍普金斯大学（JHU）和得克萨斯州医学中心内的其他卓越中心，提供 为促进PDAC和CRC的创新转化研究项目提供了前所未有的温床。预处理 该计划将以一页意向书（LOI）的形式征求建议书，并在审查后由 DRP领导层，将邀请响应预建议书的申请人提交完整的建议书供审查。 DRP主任将帮助研究人员提交建议，以制定转化研究目标和计划 与GI SPORE的总体主题相关，因为许多申请人可能之前没有此类专业知识 research.总体目标将是促进研究活动，使提出一个可行的人类 供资提案未来迭代的终点。因此，这一进程将是一项重要的教育活动 这将进一步促进CRC或PDAC的转化研究，并鼓励 包括基础科学研究人员和临床研究人员。

DEVELOPMENTAL RESEARCH PROGRAM: Summary/Abstract The purpose of the Developmental Research Program (DRP) is to fund highly innovative translational studies in colorectal cancer (CRC) or pancreatic cancer (PDAC) that currently lack a human endpoint as mandated by the SPORE guidelines, but that could become full SPORE projects with requisite DRP support, or compete successfully for funding outside of the SPORE mechanism. The DRP provides a unique venue for making available critical financial support, as well as disease-specific intellectual and resource expertise, through a program that is rapidly responsive to new ideas or initiatives, including from investigators whose current work may not focus exclusively in CRC or PDAC research. This program is rooted in a spirit of collaboration espoused by the GI SPORE leadership, which has an extensive track record of bringing investigators from other disciplines into the field of CRC and/or PDAC research. The strength of the DRP rests in its ability to make available financial support needed to access all the critical expertise and resources within the entire GI SPORE, including the proposed Cores. This will allow us to develop innovative, investigator-initiated projects that have the potential to flourish into reliable and productive translational research projects along a path from basic and/or population research projects into research focused on human clinical specimens/patient populations. The DRP will be co- led by principal investigators of the SPORE including Dr. Anirban Maitra, the Scientific Director of the Sheikh Ahmed Center for Pancreatic Cancer Research, and Professor in the Departments of Pathology and Translational Molecular Pathology at UT MD Anderson Cancer Center (UTMDACC) and Dr. Scott Kopetz, Associate Professor and Deputy Chair for Translational Research in the Department of Gastrointestinal Medical Oncology. The DRP will incorporate not only UTMDACC, but also our collaborating partner institution Johns Hopkins University (JHU) and other centers of excellence within the Texas Medical Center, providing an unprecedented seedbed for promoting innovative translational research projects in PDAC and CRC. Pre- proposals in the form of one page letters of intent (LOI) will be solicited by the Program, and following review by the DRP leadership, applicants of the responsive pre-proposals will be invited to submit a full proposal for review. The DRP Directors will help investigators submitting proposals to formulate translational research aims and plans relevant to the overall themes of the GI SPORE, as many applicants may not have prior expertise in this type of research. The overarching goal will be to facilitate research activities that will enable proposing a feasible human endpoint for future iterations of the funded proposal. This process will therefore be a major educational activity that is further anticipated to stimulate translational research in CRC or PDAC and encourage the participation of both basic science researchers and clinical investigators in translational research.